Core Viewpoint - The company has received the first clinical trial approval for an mRNA vaccine for economic animals in China, marking a significant milestone in its veterinary mRNA vaccine development platform [1] Group 1: Company Developments - The company, 瑞普生物, announced that it has obtained a clinical trial approval from the Ministry of Agriculture and Rural Affairs for its mRNA vaccine targeting porcine epidemic diarrhea virus (RPS1903) [1] - This approval signifies that the company possesses a mature research and development platform for veterinary mRNA vaccines, which is expected to broaden its product line and development opportunities [1] Group 2: Industry Context - The approval of the mRNA vaccine is a pioneering step in the domestic market for economic animals, indicating a potential shift in veterinary vaccine development [1] - It is important to note that after obtaining clinical trial approval, the vaccine must complete clinical trials and submit for registration, which involves review and approval by the Ministry of Agriculture and Rural Affairs before it can be marketed [1]

Core Viewpoint - The announcement indicates that the company has received clinical trial approval for its mRNA vaccine targeting porcine epidemic diarrhea virus, marking a significant milestone in the veterinary vaccine sector in China [1] Group 1 - The company has obtained the clinical trial approval for the porcine epidemic diarrhea virus mRNA vaccine (RPS1903) from the Ministry of Agriculture and Rural Affairs [1] - This approval represents the first clinical trial permit for an mRNA vaccine for economic animals in China [1] - The achievement highlights the company's established mRNA vaccine research and development platform for veterinary use, which is expected to broaden its product line and development potential [1] Group 2 - The approval is anticipated to enhance the company's visibility and influence within the industry [1]

证券代码：300119 证券简称：瑞普生物 公告编号：2025-056 瑞普生物股份有限公司 近日，瑞普生物股份有限公司（以下简称"公司"）收到了农业农村部颁发 的猪流行性腹泻病毒 mRNA 疫苗（RPS1903）临床试验批件（批件号：2025061）， 现将相关情况公告如下： 一、临床批件主要内容 | 项目名称 | 猪流行性腹泻病毒 疫苗（RPS1903）临床试验 mRNA | | --- | --- | | 受理号 | 07020020250519-52 | | 审批结论 | 同意申请单位在有效期限内在批准的试验地点进行临床试验 | | 申请单位名称 | 瑞普生物股份有限公司、天津瑞普生物技术股份有限公司空港经 | | | 济区分公司、瑞普（保定）生物药业有限公司 | | 临床试验承担单位 | 天津渤海农牧产业联合研究院有限公司 | 二、项目的主要情况 猪流行性腹泻，是由猪流行性腹泻病毒引起的一种高度接触性肠道传染病。 该病毒主要侵蚀猪的肠道，致使病猪出现严重腹泻、呕吐、脱水等症状，尤其对 新生仔猪的致死率极高。一旦猪场爆发猪流行性腹泻，病毒会迅速在猪群中传播， 造成大量仔猪死亡，给养殖户带来巨大的经济损 ...

Group 1: Non-ferrous Metals - Tin Industry - The company, Xiyie Co., is a global leader in the tin and indium industry, expected to benefit significantly from the rising price center, leading to profit enhancement. The company has excellent resource endowments with substantial growth potential in tin, tungsten, and indium production [2][4]. - The domestic market share of the company in tin metal is projected to reach 47.98% in 2024, with a global market share of 25.03%, positioning it as the top tin producer worldwide. The company plans to invest 101 million yuan in exploration, adding 52,400 tons of non-ferrous metal resources in 2024 [4]. - The company is actively pursuing both internal resource development and external partnerships to enhance its industry chain advantages, with a production scale of 1.5 million tons/year for tin and 560,000 tons/year for tungsten planned [4][5]. Group 2: Agriculture - Animal Health Industry - Ruip Bio is a leading player in the domestic animal health industry, with robust growth in both livestock and pet health segments. The company is expected to see steady progress in livestock health and rapid growth in pet health products, with a projected market size of 20.95 billion yuan for pet medicine by 2024 [6][7]. - The company has achieved a compound annual growth rate of over 16% in revenue from 2015 to 2024, with total revenue expected to reach 3.07 billion yuan in 2024. The company has established a strong presence in over 70 cities through strategic acquisitions and partnerships [7]. - The company is focusing on enhancing its product matrix in pet health, with a significant emphasis on vaccine development, including a breakthrough in the cat trivalent vaccine, which is expected to double revenue in 2025 [6][7]. Group 3: Communication - New Yi Sheng - New Yi Sheng has raised its earnings forecast and target price, maintaining a buy rating. The company is expected to achieve a net profit of 3.7 to 4.2 billion yuan in the first half of 2025, representing a year-on-year growth of 327.68% to 385.47% [9][10]. - The company is expanding its production capacity, with the first phase of its factory in Thailand completed in the first half of 2023 and the second phase expected to be operational in early 2025. The demand for 1.6T products is anticipated to begin ramping up in the second half of 2025 [10].

Core Viewpoint - The veterinary raw material drug market in China is expected to grow significantly, with a projected market size of approximately 185.1 billion yuan in 2024 and around 200 billion yuan in 2025, driven by increased demand and favorable economic conditions [1][8]. Industry Characteristics and Classification - Veterinary raw material drugs are pharmacologically active substances used directly in the manufacture of veterinary drug formulations, characterized by specificity, regulatory requirements, and high technical barriers [2][4]. - They can be classified by chemical properties into synthetic raw materials, biotechnological raw materials, and natural extracts, and by usage into antimicrobial drugs, antiparasitic drugs, antipyretic analgesics, and diagnostic/treatment aids [4][5]. Current Development Status - The veterinary drug industry in China has rapidly developed, becoming a significant part of the global veterinary drug market, with a projected market size of approximately 600 billion yuan in 2024 and 635 billion yuan in 2025 [6][8]. Market Size and Growth - The veterinary raw material drug market is expected to see a growth from 185.1 billion yuan in 2024 to 200 billion yuan in 2025, reflecting a recovery in demand and controlled supply [8][10]. Market Segmentation - Antimicrobial drugs dominate the veterinary raw material drug market, holding an 84% market share, while antiparasitic drugs account for about 11% [10]. Industry Chain - The industry chain includes upstream components such as basic chemical raw materials and intermediates, midstream production of raw materials through chemical synthesis and fermentation, and downstream processing into veterinary drug formulations for livestock and pet healthcare [12]. Competitive Landscape - The veterinary raw material drug industry in China has a low concentration level, with major companies including Haisheng Pharmaceutical, Qihui Pharmaceutical, Guobang Pharmaceutical, and Puluo Pharmaceutical, among others [14][16]. - The industry is experiencing a shift towards larger, more capable firms as regulatory standards improve, leading to a potential increase in market concentration [14]. Key Enterprises - Guobang Pharmaceutical reported a revenue of 1.831 billion yuan from animal health raw materials in 2024, with a gross margin of 18.86% [16]. - Haisheng Pharmaceutical achieved a revenue of 112 million yuan from raw materials in 2024, with a gross margin of 36.28% [18]. Technology Development Trends - The production of raw materials and intermediates requires significant investment in research and development to improve process technology and compete in higher-margin sectors [20].

Investment Rating - The report maintains a "Recommended" rating for the agricultural, forestry, animal husbandry, and fishery industry [1][8][64] Core Viewpoints - The report highlights the long-term value reassessment opportunities in the pig industry, with expectations of price fluctuations in the range of 14-15 CNY/kg post-Chinese New Year 2025, indicating a potential downward trend in prices due to supply pressures [4][15] - The poultry sector is experiencing price declines, with a focus on marginal improvements in the cycle, while the animal health sector is expected to see performance recovery and investment opportunities in the pet medical industry [5][6][28] - The pet economy is thriving, with domestic brands rapidly emerging, and the report anticipates continued improvement in industry profitability [7][58] Summary by Sections 1. Pig Industry - The average price of pigs is currently around 14.6 CNY/kg, with a slight weekly decline [14] - The report recommends companies with low costs and strong financials, specifically highlighting Wens Foodstuffs, Muyuan Foods, and Juxing Agriculture [15][64] 2. Poultry Industry - The report notes a decline in poultry prices, with a focus on the cyclical improvements expected in the future [27] - Recommendations include Shennong Development and Lihua Stock [5][28] 3. Animal Health - The animal health sector is expected to see a recovery in performance, supported by the profitability of the pig farming industry [6][38] - Investment opportunities in the pet medical sector are highlighted, with a market size of approximately 840 billion CNY [7][38] 4. Planting Industry - The report indicates a decrease in wheat and corn prices, with recommendations for companies involved in genetically modified seeds [44][50] 5. Feed Industry - The total industrial feed production in the first half of 2025 reached 15,850 million tons, showing a year-on-year growth of 7.7% [48][50] - Recommendations include Haida Group and attention to He Feng Stock [50] 6. Pet Industry - The pet consumption market is projected to reach 300.2 billion CNY in 2024, with a growth rate of 7.5% [55][58] - Recommended companies in the pet food sector include Guai Bao Pet, Zhongchong Stock, and Petty Stock [58][64]

Overview - The role of pets in families is evolving from animals to family members, leading to a significant increase in pet owners' focus on pet health and a willingness to purchase health products for pets [1][12] - The market for pet health products in China is projected to reach 12.65 billion yuan in 2024, with a year-on-year growth of 15.73%, and over 80% of this market is attributed to dog and cat health products [1][12] Development Background - The increase in pet ownership is driven by demographic changes such as an aging population, rising divorce rates, and declining birth rates, leading to more people seeking companionship from pets [6][10] - Over 90% of pet owners now consider their pets as family members, which enhances their willingness to spend on pet care, thus driving the growth of the pet health product market [6][10] Industry Chain - The upstream of the pet health product industry includes suppliers of basic nutritional raw materials such as vitamins and minerals, as well as functional raw materials like glucosamine and probiotics [8] - The midstream involves the production and manufacturing of pet health products, while the downstream includes sales channels such as pet stores, veterinary clinics, and e-commerce platforms [8] Current Market Situation - The demand for pet health products is becoming more refined and personalized, with increasing interest in products targeting specific health functions such as joint protection and digestive care [1][12] - Companies are encouraged to develop more personalized products to meet the diverse needs of different pet breeds, ages, sizes, and health conditions [1][12] Competitive Landscape - The pet health product market in China is relatively concentrated, with key players including Shanghai Hongxing Pet Products Co., Ltd., Shenzhen Hongrui Biotechnology Co., Ltd., and others [15][17] - Notable companies like Guobao Pet Food Group Co., Ltd. reported a total revenue of 5.245 billion yuan in 2024, with health products contributing 0.46 billion yuan, accounting for 0.88% of total revenue [19] Future Trends - Functional health products such as those for joint health and immune support are expected to dominate the market, while personalized health products based on genetic testing and AI algorithms are anticipated to emerge [21] - There is a growing consumer preference for natural and organic ingredients in pet health products, aligning with concerns about food safety and health [21]

Core Viewpoint - Reap Bio announced a profit forecast for the first half of 2025, expecting a non-GAAP net profit of 180 million to 209 million yuan, representing a year-on-year growth of 30% to 50%, and a net profit attributable to shareholders of 240 million to 276 million yuan, indicating a growth of 50% to 70% [1][2]. Financial Performance - The net profit attributable to shareholders is projected to be between 244.16 million yuan and 276.72 million yuan, a growth of 50% to 70% compared to 162.78 million yuan in the same period last year [2]. - The non-GAAP net profit is expected to be between 181.75 million yuan and 209.72 million yuan, reflecting a growth of 30% to 50% from 139.81 million yuan in the previous year [2]. Business Growth Drivers - The company attributes its performance increase to four main factors: strategic partnerships with large breeding enterprises, focus on high-potential sectors like pet healthcare and overseas markets, operational efficiency improvements, and a robust management system [3][4]. - The pet healthcare segment is becoming a key growth driver, with significant revenue increases in new business areas [4][6]. Segment Performance - The pet supply chain business grew by 37.66% year-on-year, reaching 633 million yuan, accounting for 20.63% of total revenue [5]. - The pet biological products segment saw an impressive growth of 849.09%, achieving revenue of 37.44 million yuan, marking it as a standout performer [5]. Market Position and Strategy - Reap Bio has expanded its market presence by acquiring the Zhongrui supply chain platform, which now covers 7,000 pet hospitals and 3,400 pet stores across China [6]. - The company aims to enhance its product offerings and market penetration in the pet healthcare sector, focusing on building a comprehensive ecosystem that integrates research, validation, distribution, and service [9]. Future Outlook - The company plans to continue expanding its pet supply chain market coverage and revenue scale through capital operations and deepening product penetration in pet hospitals and stores [9]. - Despite the growth, the company acknowledges challenges such as increasing competition in the veterinary medicine market and the need for continuous innovation in product development [10].

Market Overview - A-shares maintained a narrow fluctuation on July 16, with the Shanghai Composite Index closing at 3503.78 points, down 0.03% [1] - The Shenzhen Component Index and the ChiNext Index both fell by 0.22% to 10720.81 points and 2230.19 points, respectively [1] - The total trading volume in the Shanghai and Shenzhen markets was 146.19 billion yuan, a decrease of over 170 billion yuan from the previous day [1] Sector Performance - Financial stocks collectively declined, while the steel, non-ferrous metals, and coal sectors showed weakness [1] - The automotive supply chain stocks surged, with companies like Rongtai Co., Fuda Co., and Zhejiang Rongtai hitting the daily limit [1] - The innovative drug concept saw significant activity, with stocks like Guosheng Tang and Iwu Biotech rising approximately 16% [5][6] - The humanoid robot concept remained hot, with companies like Shangwei New Materials achieving a six-day limit increase [2][4] Notable Company Movements - Huadian New Energy, which debuted on the Shanghai main board, closed up 125.8%, reaching a market value of over 300 billion yuan at one point [1] - Weiyali, a Hong Kong-based electronic component distributor, saw its stock surge by 288% upon resuming trading, with an intraday increase exceeding 900% [1] Humanoid Robot Sector Insights - The humanoid robot industry is in its early stages, with significant growth expected in the next 3 to 5 years across various applications [4] - The current phase is described as the "dawn" of humanoid robot industrialization, with mass production and large-scale application becoming feasible [4] - Cost reduction is crucial for the widespread adoption of humanoid robots, and companies that master core component technologies are recommended for investment [4] Innovative Drug Sector Insights - The innovative drug sector experienced strong gains, with several companies hitting the daily limit [5][6] - The recent launch of the 11th batch of national drug centralized procurement is expected to impact the market, focusing on mature "old drugs" rather than innovative drugs [7] - The introduction of measures to support the high-quality development of innovative drugs indicates a growing role for commercial insurance in the healthcare system [7] Pet Economy Sector Insights - The pet economy concept gained traction, with companies like Weike Technology rising over 10% [8] - The pet food sector is viewed as a growing market with significant long-term growth potential, particularly for domestic brands [8]

Group 1 - The animal vaccine sector saw a rise of 2.91%, leading the concept sectors in growth, with 16 stocks increasing in value, including BioShares which hit the daily limit, and others like Kexing Pharmaceutical and Ruipu Bio rising by 7.15%, 5.65%, and 3.56% respectively [1] - The main inflow of funds into the animal vaccine sector was 281 million yuan, with 10 stocks receiving net inflows, and 6 stocks seeing inflows exceeding 10 million yuan, led by BioShares with a net inflow of 159 million yuan [1] - The top stocks by net inflow included Haizheng Pharmaceutical, Kexing Pharmaceutical, and Ruipu Bio, with net inflows of 53.91 million yuan, 52.39 million yuan, and 28.10 million yuan respectively [1] Group 2 - In terms of fund inflow ratios, BioShares, Kexing Pharmaceutical, and Luoniushan had the highest net inflow rates at 19.39%, 9.63%, and 8.85% respectively [2] - The animal vaccine concept fund inflow rankings showed BioShares with a daily increase of 10.04% and a turnover rate of 8.74%, while Haizheng Pharmaceutical and Kexing Pharmaceutical followed with increases of 2.71% and 7.15% respectively [2] - Other notable stocks included Ruipu Bio with a 5.65% increase and a turnover rate of 9.16%, and Luoniushan with a 3.49% increase and a turnover rate of 4.43% [2]